You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

NOCTIVA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Noctiva patents expire, and when can generic versions of Noctiva launch?

Noctiva is a drug marketed by Acerus Pharms and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and seventeen patent family members in thirty-one countries.

The generic ingredient in NOCTIVA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Noctiva

A generic version of NOCTIVA was approved as desmopressin acetate by MEITHEAL on October 15th, 1997.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NOCTIVA?
  • What are the global sales for NOCTIVA?
  • What is Average Wholesale Price for NOCTIVA?
Drug patent expirations by year for NOCTIVA
Drug Prices for NOCTIVA

See drug prices for NOCTIVA

US Patents and Regulatory Information for NOCTIVA

NOCTIVA is protected by four US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NOCTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 ⤷  Subscribe ⤷  Subscribe
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 ⤷  Subscribe ⤷  Subscribe
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 ⤷  Subscribe ⤷  Subscribe
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 ⤷  Subscribe ⤷  Subscribe
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NOCTIVA

See the table below for patents covering NOCTIVA around the world.

Country Patent Number Title Estimated Expiration
Japan 2006502972 ⤷  Subscribe
Russian Federation 2012101619 ⤷  Subscribe
New Zealand 593613 INTRANASAL DESMOPRESSIN ADMINISTRATION ⤷  Subscribe
South Korea 20120046176 SAFE DESMOPRESSIN ADMINISTRATION ⤷  Subscribe
Japan 2018184407 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NOCTIVA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3225249 CA 2019 00023 Denmark ⤷  Subscribe PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
3225249 2019C/520 Belgium ⤷  Subscribe PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622 122017000006 Germany ⤷  Subscribe PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
3225249 300983 Netherlands ⤷  Subscribe PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
2712622 C02712622/01 Switzerland ⤷  Subscribe PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

NOCTIVA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for NOCTIVA

Introduction

NOCTIVA, a desmopressin acetate nasal spray, is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults. This article delves into the market dynamics and financial trajectory of NOCTIVA, highlighting its launch, performance, and the challenges it has faced.

Market Need and Target Population

NOCTIVA addresses a significant medical need by treating nocturia, a condition characterized by the need to urinate at least twice during the night. The target population includes adults, particularly those 50 years and older, with nocturnal polyuria, which is defined as night-time urine production exceeding one-third of the 24-hour urine production[4].

Launch and Initial Performance

NOCTIVA was launched in March 2018 by Avadel Pharmaceuticals. The initial performance was marked by significant marketing efforts, with sales and marketing costs associated with the launch amounting to approximately $48,500. This was partially offset by lower SG&A spend related to the divestiture of Avadel's pediatric assets[3].

Clinical Efficacy and Quality of Life Impact

Clinical trials demonstrated that NOCTIVA significantly improved the quality of life for patients. Patients treated with NOCTIVA were three times more likely to report no difficulty getting enough sleep and five times more likely to report no bother due to nocturia compared to baseline levels. At the end of 12 weeks, a substantial percentage of patients reported no difficulty getting enough sleep and no bother due to nocturia[1].

Financial Performance

Revenue

In the year ended December 31, 2018, NOCTIVA contributed $1,204 to Avadel's total product sales. This was a modest start, given that the product was launched mid-year. The overall revenue for Avadel during this period was $101,423, down from $172,841 in the prior year, primarily due to declines in other product lines such as Bloxiverz and Akovaz[3].

Gross Profit and Expenses

The gross profit for Avadel in 2018 decreased by 45.4% to $85,753, largely due to decreased turnover of other products. The launch of NOCTIVA added to the research and development (R&D) costs, which increased by 17.7% during the year. Distribution and administrative expenses also rose significantly, driven by the marketing costs for NOCTIVA[3].

Challenges and Risks

Market Competition

NOCTIVA faces competition from other treatments for nocturia. Avadel's internal analyses may overstate the market opportunity, and the company must effectively increase awareness of nocturia and the benefits of NOCTIVA to capture market share[1].

Safety and Drug Interactions

One of the significant risks associated with NOCTIVA is the potential for hyponatremia, particularly in older patients and those taking concomitant medications like systemic or inhaled glucocorticoids and NSAIDs. This risk necessitates careful patient monitoring and management[4].

Financial Risks

Avadel's financial performance is also subject to various risks, including those related to its exchangeable senior notes, the divestiture of its pediatric business, and the license agreement with Serenity Pharmaceuticals. These factors can impact the company's ability to successfully commercialize NOCTIVA[1].

Acquisition and Current Status

In 2022, Acerus Pharmaceuticals acquired Serenity and the global rights to NOCTIVA. This acquisition marked a new chapter in the drug's commercialization. Acerus reported improved revenue in 2021, partly due to the growth in product sales, including those related to NOCTIVA[5].

Financial Results Post-Acquisition

Acerus's financial results for 2021 showed a net loss, but the company saw improvements in gross profit compared to the prior year. The acquisition of NOCTIVA and other products contributed to this improvement, despite ongoing challenges such as high research and development costs and significant operating expenses[5].

Key Takeaways

  • Market Need: NOCTIVA addresses a significant medical need for adults with nocturia due to nocturnal polyuria.
  • Clinical Efficacy: The drug has shown substantial improvements in patients' quality of life.
  • Financial Performance: Initial revenue was modest, with significant marketing and R&D expenses.
  • Challenges: Market competition, safety risks, and financial uncertainties pose challenges.
  • Acquisition: Acerus's acquisition of NOCTIVA has marked a new phase in its commercialization.

FAQs

What is NOCTIVA used for?

NOCTIVA is used for the treatment of nocturia due to nocturnal polyuria in adults.

When was NOCTIVA launched?

NOCTIVA was launched in March 2018 by Avadel Pharmaceuticals.

What are the clinical benefits of NOCTIVA?

Patients treated with NOCTIVA are more likely to report no difficulty getting enough sleep and no bother due to nocturia.

What are the potential risks associated with NOCTIVA?

One of the significant risks is the potential for hyponatremia, particularly in older patients and those taking certain concomitant medications.

Who currently holds the rights to NOCTIVA?

Acerus Pharmaceuticals acquired the global rights to NOCTIVA in 2022.

Sources

  1. Avadel Pharmaceuticals: "Avadel Presents Data on Quality of Life Improvement in Patients on NOCTIVAâ„¢" - October 29, 2018.
  2. BioSpace: "Acerus Reports Second Quarter 2022 Financial Results" - August 9, 2022.
  3. Avadel Pharmaceuticals: "AVADEL PHARMACEUTICALS PLC" - June 13, 2019.
  4. RxList: "Noctiva (Desmopressin Acetate Nasal Spray)".
  5. GlobeNewswire: "Acerus Reports Fourth Quarter and Full Year 2021 Financial Results" - March 15, 2022.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.